IMUX Projected Dividend Yield
Immunic Inc ( NASDAQ : IMUX )Immunic is a clinical-stage biopharmaceutical company. Co. is pursuing three development programs. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase; the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated, an immune cell-specific isoform of retinoic acid receptor-related orphan nuclear receptor gamma; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. 20 YEAR PERFORMANCE RESULTS |
IMUX Dividend History Detail IMUX Dividend News IMUX Competitors News |
Year | Declaration Date | Ex-Dividend Date | Record Date | Payable Date | Dividend $ Amount |
Total: | 0.0000 |